{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:48:23Z","timestamp":1789069703206,"version":"build-2803163510"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Factor H (FH) is a crucial complement regulator that prevents complement-mediated injury to healthy cells and tissues. This regulatory function can be disrupted by Factor H autoantibodies (FHAA), which then leads to diseases such as atypical hemolytic uremic syndrome (aHUS) and C3 Glomerulopathy (C3G). In pediatric aHUS, the FHAA incidence is ~10-15%, although in the Indian population, it rises to ~50%. The specific regions of FH targeted by FHAAs correlate with the pathogenic mechanism of the associated disease. In aHUS, FHAAs target the C-terminus, thereby impacting FH ability to recognize cell surfaces. In C3G, in contrast, FHAAs often target the N-terminus, generating an acquired functional FH deficiency. Detection and monitoring FHAAs are decisive for effectively treating patients. Current FHAA analysis normally identify free FHAAs that bind surface-bound FH using ELISA techniques. These methods require well-equipped laboratories and qualified staff, and do not measure FH-FHAA complexes, which can make it difficult to correlate titers with clinical outcomes. The visually-based immunochromatographic test (ICT) described herein allows for quick detection and quantification of IgG and IgM FH-FHAA complexes in human EDTA-plasma or serum. This ICT offers improved detection of FHAAs compared to ELISA as demonstrated by cases where the ICT identifies FH-FHAA complexes in samples that tested negative with the free FHAA ELISA. Importantly, the ICT indirectly informs on the amount of FH that is complexed with FHAAs, thus assessing the significance of the FHAA in disrupting the regulatory function of FH. Overall, this novel assay offers a simple, fast, cost-effective, and, likely, more clinically relevant alternative for diagnosing FHAAs in at-risk populations.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1527016","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:15:50Z","timestamp":1737702950000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel immunochromatographic test for rapid detection of anti-factor H autoantibodies with an assessment of its clinical relevance"],"prefix":"10.3389","volume":"15","author":[{"given":"Santiago","family":"Rodr\u00edguez de C\u00f3rdoba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Reparaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Juana Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Martin Merinero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iria","family":"Calvete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Perez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney S.","family":"Jellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J. H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.02.005","article-title":"The human complement factor H: Functional roles, genetic variations and disease associations","volume":"41","author":"Rodr\u00edguez De C\u00f3rdoba","year":"2004","journal-title":"Mol Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.99","article-title":"Anti-complement-factor H-associated glomerulopathies","volume":"12","author":"Durey","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01260212","article-title":"Complement factor H\u2013related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome","volume":"8","author":"Hofer","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ped.12549","article-title":"Atypical hemolytic uremic syndrome: Korean pediatric series","volume":"57","author":"Lee","year":"2015","journal-title":"Pediatr Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"R185","DOI":"10.1186\/ar4016","article-title":"Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome","volume":"14","author":"Foltyn Zadura","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.607211","article-title":"Factor H autoantibodies and complement-mediated diseases","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01282","article-title":"Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: A nationwide database","volume":"10","author":"Puraswani","year":"2019","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-109876","article-title":"Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency","volume":"111","author":"J\u00f3zsi","year":"2008","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223834","article-title":"Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome","volume":"114","author":"Abarrategui-Garrido","year":"2009","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-024-01961-4","article-title":"IgM autoantibodies to complement factor H in C3 glomerulopathy","volume":"37","author":"Cugno","year":"2024","journal-title":"J Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020081224","article-title":"IgM autoantibodies to complement factor H in atypical hemolytic uremic syndrome","volume":"32","author":"Cugno","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200679","article-title":"Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome","volume":"189","author":"Blanc","year":"2012","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-071472","article-title":"Anti-factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome","volume":"110","author":"J\u00f3zsi","year":"2007","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.molimm.2015.12.005","article-title":"Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome","volume":"70","author":"Nozal","year":"2016","journal-title":"Mol Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.imbio.2013.06.004","article-title":"Standardisation of the factor H autoantibody assay","volume":"219","author":"Watson","year":"2014","journal-title":"Immunobiology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-0357-x","article-title":"Tutorial: design and fabrication of nanoparticle-based lateral-flow immunoassays","volume":"15","author":"Parolo","year":"2020","journal-title":"Nat Protoc"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1527016\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:15:53Z","timestamp":1737702953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1527016\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2024.1527016"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1527016","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"article-number":"1527016"}}